Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



JOHNSON & JOHNSON Stock Hits Price Target Forecast, Yielding Profit of 5.71%

July 25, 2024
JOHNSON & JOHNSON (JNJ) investors have seen their patience pay off as the stock recently hit the price target forecast provided by QuantWave, resulting in a profit of 5.71%. The forecast signal was issued on July 16, 2024, with the stock trading at 146.25 $. The predicted direction was long, and on July 25, 2024, the price reached 154.6 $. This successful forecast highlights the accuracy and reliability of QuantWave's analytics in predicting stock movements.

Several factors may have contributed to JOHNSON & JOHNSON's positive price movement. The company's strong financial performance, innovative product portfolio, and robust pipeline of new products could have instilled confidence among investors, leading to an increase in demand for the stock. Additionally, positive industry trends and global economic conditions may have also played a role in driving up JOHNSON & JOHNSON's stock price.

QuantWave is an automated forecasting platform that offers users access to predictions for a wide range of stocks, providing opportunities for potential profits. For investors looking to enhance their understanding of QuantWave's investment strategy, exploring the educational resources of QuantSchool is recommended. QuantSchool offers a comprehensive professional investment framework that reveals the key principles for generating consistent income using the QuantWave forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....

JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....

JNJFebruary 18, 2025Johnson & Johnson reportedly wants to sell Cerenovus for 1B  ~1 min.

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

JNJFebruary 16, 2025Johnson & Johnson Explores Sale of Cerenovus for $1 Billion  ~1 min.

According to reports, pharmaceutical giant Johnson & Johnson is looking to sell its stroke care business, Cerenovus, for a staggering $1 billion....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast with 16.34% Profit: QuantWave Analysis  ~2 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) recently saw its stock reach the forecasted price target set by QuantWave, resulting in a profit of 16....

ABBVJanuary 10, 2024ABBVIE INC. Hits Price Target Forecast with 12.12% Profit: A Success for QuantWave  ~1 min.

On August 1, 2023, QuantWave, the automated forecasting platform, issued a long signal for ABBVIE INC. with a price target of $156.15....

ETNOctober 14, 2024QuantWave Achieves 16.82% Profit Target Forecast for Eaton Corporation PLC  ~1 min.

QuantWave, a leading automated forecasting platform, recently achieved a significant milestone by accurately predicting a 16.82% profit target for Eaton Corporation PLC....

ENBSeptember 16, 2024ENBRIDGE INC. Stock Hits Forecasted Price Target with a Profit of 13.88%  ~1 min.

QuantWave, a leading automated forecasting platform, successfully predicted the price movement of ENBRIDGE INC. stock with a profit of 13.88%....

AAPLDecember 16, 2024QuantWave Achieves 32.43% Profit Target for APPLE INC. Stock Forecast  ~2 min.

QuantWave, the automated forecasting platform, has successfully hit its price target forecast for APPLE INC. stock, signaling a 32.43% profit....